---
title: "CSPC PHARMA: Strong Aldosterone Synthase Inhibitor (SYH2072 Tablets) Approved for Clinical Trials in China"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270982244.md"
description: "CSPC PHARMA announced that its new drug, a potent aldosterone synthase inhibitor (SYH2072 tablets), has been approved by the National Medical Products Administration of China for clinical trials. This drug can effectively reduce plasma aldosterone levels, with indications including uncontrolled hypertension and primary aldosteronism, and it has good pharmacokinetic properties and safety, showing potential to become a best-in-class medication"
datetime: "2025-12-29T10:32:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270982244.md)
  - [en](https://longbridge.com/en/news/270982244.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270982244.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/270982244.md) | [English](https://longbridge.com/en/news/270982244.md)


# CSPC PHARMA: Strong Aldosterone Synthase Inhibitor (SYH2072 Tablets) Approved for Clinical Trials in China

According to the announcement from CSPC PHARMA (01093), the group has developed a Class 1 new chemical drug, a potent aldosterone synthase inhibitor (SYH2072 tablets), which has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.

This product is a highly selective potent aldosterone synthase inhibitor (ASI) that can effectively reduce plasma aldosterone levels without affecting cortisol levels. The approved clinical indications are uncontrolled hypertension and primary aldosteronism. Preclinical studies have shown that this product can selectively inhibit aldosterone synthase activity, significantly reduce plasma aldosterone levels in animal disease models, and dose-dependently lower blood pressure in hypertension models, while not affecting cortisol levels. The product has good pharmacokinetic (PK) characteristics and safety, giving it the potential to become a best-in-class drug. Currently, the group has submitted multiple patent applications for this product both domestically and internationally.

Given the broad clinical demand for aldosterone synthase inhibitors, this product has high clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and primary aldosteronism

### 相關股票

- [CSPC PHARMA (01093.HK)](https://longbridge.com/zh-HK/quote/01093.HK.md)

## 相關資訊與研究

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/zh-HK/news/280415449.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/zh-HK/news/280502605.md)
- [ZAWYA: NYU Abu Dhabi and University of Denver Researchers identify promising small molecule inhibitor of brain disorders like parkinson’s disease](https://longbridge.com/zh-HK/news/281500635.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [Does Strong Lecanemab Treatment Persistence Reshape The Bull Case For Eisai (TSE:4523)?](https://longbridge.com/zh-HK/news/280962864.md)